Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.

Blauvelt, Andrew; Reich, Kristian; Tsai, Tsen-Fang; Tyring, Stephen; Vanaclocha, Francisco; Kingo, Külli; Ziv, Michael; Pinter, Andreas; Vender, Ronald; Hugot, Sophie; You, Ruquan; Milutinovic, Marina; Thaçi, Diamant

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.

Blauvelt, Andrew; Reich, Kristian; Tsai, Tsen-Fang; Tyring, Stephen; Vanaclocha, Francisco; Kingo, Külli; Ziv, Michael; Pinter, Andreas; Vender, Ronald; Hugot, Sophie; You, Ruquan; Milutinovic, Marina; Thaçi, Diamant.

Afiliação

Blauvelt A; Oregon Medical Research Center, Portland, Oregon. Electronic address: ablauvelt@oregonmedicalresearch.com.
Reich K; Dermatologikum Hamburg and SCIderm Research Institute, Hamburg, Germany.
Tsai TF; National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
Tyring S; University of Texas Health Science Center at Houston, Center for Clinical Studies, Houston, Texas.
Vanaclocha F; Hospital Universitario 12 de Octubre, Madrid, Spain.
Kingo K; Dermatology Clinic, Tartu University Hospital, Tartu, Estonia.
Ziv M; Emek Medical Center, Afula, Israel.
Pinter A; Goethe Universität Frankfurt am Main, Frankfurt, Germany.
Vender R; McMaster University, Hamilton, Ontario, Canada.
Hugot S; Novartis Pharma AG, Basel, Switzerland.
You R; Novartis Beijing Novartis Pharma Co. Ltd, Shanghai, China.
Milutinovic M; Novartis Pharma AG, Basel, Switzerland.
Thaçi D; Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany.

J Am Acad Dermatol ; 76(1): 60-69.e9, 2017 Jan.

Article em En | MEDLINE | ID: mdl-27663079

Assuntos

Anticorpos Monoclonais/uso terapêutico; Fármacos Dermatológicos/uso terapêutico; Psoríase/tratamento farmacológico; Ustekinumab/uso terapêutico; Adulto; Anticorpos Monoclonais/efeitos adversos; Anticorpos Monoclonais Humanizados; Fármacos Dermatológicos/efeitos adversos; Método Duplo-Cego; Feminino; Humanos; Masculino; Pessoa de Meia-Idade; Índice de Gravidade de Doença; Resultado do Tratamento; Ustekinumab/efeitos adversos

Palavras-chave

Psoriasis Area and Severity Index (PASI); clinical trial; efficacy; psoriasis; safety; secukinumab; ustekinumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Psoríase / Fármacos Dermatológicos / Ustekinumab / Anticorpos Monoclonais Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google